with PSK and 5-FU (CIP), Aichi Japan PURPOSE: Protein-bound polysaccharide K is an immunotherapeutic agent that promotes apoptosis by inhibiting nuclear factor-kappaB activation in cancer cells. We previously showed that oncogenic "-catenin activates nuclear factor-kappaB and inhibits apoptosis by up-regulating "-transducin repeat-containing protein. We investigated whether the activation state of "-catenin in the primary tumor is associated with differences in survival rates of patients with colon cancer undergoing immunochemotherapy with 5-fluorouracil plus polysaccharide K vs. chemotherapy with 5-fluorouracil alone. METHODS: We assessed the activation states of "-catenin and nuclear factor-kappaB in the primary tumors of 202 colon cancer patients, and analyzed the data in terms of the clinicopathologic characteristics and survival of patients undergoing the two forms of adjuvant therapy. RESULTS: We found two distinct patterns of nuclear accumulation of activated "-catenin in the tumor cells: diffuse nuclear accumulation in 89 cases (44 percent) and selective nuclear accumulation at the tumor invasion front in 18 cases (9 percent). Nuclear factor-kappaB activation was found in 64 cases (32 percent). In patients with diffuse nuclear accumulationtype "-catenin activation, immunochemotherapy significantly improved recurrence-free survival, cancer death survival, and overall survival rates compared with patients receiving chemotherapy alone. No survival benefit was found in cases with nuclear accumulation at the tumor invasion front-type "-catenin activation or no activation. Similarly, immunochemotherapy favored the survival of patients with nuclear factor-kappaB activation. Multivariate analysis established the TNM stage and administration of polysaccharide K as independent prognostic factors in the patients with diffuse nuclear accumulation-type "-catenin activation. CONCLUSIONS: The presence of diffuse nuclear accumulation-type "-catenin activation identifies patients with colon cancer who respond better to immunotherapy with polysaccharide K.
D espite substantial advances in diagnosis and treatment, including postoperative therapies, 1, 2 colorectal cancer remains one of the leading causes of cancer morbidity and mortality. 3 The majority (approximately 80 percent) of newly diagnosed patients with colon cancer undergo curative resection that leaves no macroscopic evidence of residual tumor. Almost one-half of these patients, however, develop recurrence and die of this malignancy, 1, 3 probably because there were residual tumor cells in the blood and/or in micrometastatic foci. Therefore, adjuvant treatment (chemotherapy and radiation) is required to eradicate occult viable tumor cells or prevent them from reforming tumors. Immunotherapy has been developed to enhance the efficiency of chemotherapy and to shield host defenses from its adverse effects. 4 To achieve optimal outcomes from adjuvant therapy, it is important to identify factors that indicate which patients tend to benefit from chemotherapy and immunotherapy and suffer the least adverse effects from such treatments in the clinical setting. 5 The immunotherapeutic agent of interest in the present study is protein-bound polysaccharide K (PSK) from the mycelium of Coriolus versicolor. It has been used as a nonspecific immunostimulant for immunochemotherapy for patients with cancer for 20 years. Beneficial therapeutic effects of PSK have been demonstrated in a series of clinical studies of patients with several types of cancer. [6] [7] [8] Recently, a prospective, randomized trial comparing the therapeutic effects of adjuvant chemotherapy with 5-fluorouracil (5-FU) and immunochemotherapy with 5-FU plus PSK demonstrated a long-term survival benefit of PSK in a large cohort of patients with colon cancer. 9 Evidence has been accumulating regarding the mechanisms by which PSK modifies the host immune response against cancer cells and influences the effectiveness of chemotherapeutic agents, such as 5-FU. 10 Some molecular markers and tumor characteristics have been reported to be correlated with the survival of patients with stomach cancer treated with PSK. [11] [12] [13] [14] However, no reliable markers have been associated with the beneficial effect of adjuvant PSK treatment in colon cancer.
The multistep process involved in the development of colorectal cancer has been extensively analyzed. 15, 16 One of the emerging oncoproteins involved is "-catenin, which is frequently activated in colorectal cancer by escaping from ubiquitinmediated degradation, [17] [18] [19] [20] and is stabilized and translocated to the cell nucleus in an active and oncogenic form. 17, 18 We recently found that "-catenin activation was detectable in 50 to 65 percent of colorectal cancers and that in 40 to 50 percent of cases it accumulated in the nuclei of cells throughout the tumor (referred to as diffuse nuclear accumulation or (NAd)-type), whereas in 10 to 15 percent of cases it was present only in the nuclei of the tumor cells that formed the invasion front (referred to as selective nuclear accumulation at the tumor invasion front (NAinv)-type). 21, 22 NAinv-type "-catenin activation was associated with advanced tumor stage and recurrence and was consequently shown to identify the patients with colon cancer with less favorable survival rates. 21, 22 We have shown that in cells under physiologic conditions, Wnt/"-catenin signaling induces the expression of "-transducin repeat-containing protein ("-TrCP), which is an E3 ubiquitin ligase receptor that targets both wild-type "-catenin and inhibitor of nuclear factor-kappaB (IkB) for degradation. 23 Subsequently, we demonstrated that, in colon cancer, a negative-feedback loop between "-catenin and "-TrCP is defective, and oncogenic "-catenin-mediated up-regulation of "-TrCP results in down-regulation of IkB, thereby leading to activation of nuclear factorkappaB (NF-kB) survival signaling that protects tumor cells from apoptosis. 24 Importantly, it has been reported that PSK inhibits NF-kB activation in cancer cells and augments docetaxel-induced apoptosis. 25 These observations prompted us to investigate whether "-catenin activation in the primary tumor, or the pattern of its activation, is associated with differences in the survival rates of patients with colon cancer undergoing chemotherapy with 5-FU alone or immunochemotherapy with 5-FU and PSK. We also examined whether the activity of "-catenin in the tumor reflects NF-kB activation and influences the anticancer effect of PSK.
PATIENTS AND METHODS
The Colon Cancer with Immunochemotherapy (CIP) study group designed a prospective, randomized trial to compare the effects of adjuvant treatment by chemotherapy with 5-FU alone and by immunochemotherapy with PSK and 5-FU. This clinical trial took place between February 1991 and March 1993, and involved 441 patients who underwent curative resection of colon cancers in the 93 hospitals registered in the Chubu District of Japan. The Japan Surgical Society approved technical abilities of the surgeons who performed all operations. 9 Recently, the CIP study group reported details of the study design and the overall results of a comparison of immunochemotherapy (PSK + 5-FU) and chemotherapy (5-FU). 9 No difference was found in five-year and seven-year overall survival (OS) or recurrencefree survival (RFS) rates between the two groups of patients. However, the survival rate calculated on the basis of cancer death (cancer death survival (CDS)) was significantly higher in the patients receiving PSK + 5-FU than in those receiving 5-FU alone. 9 The present study involved 202 of 441 patients registered in the clinical trial from whom representative paraffin sections of the primary tumor were available for analysis of "-catenin 21 and NF-kB activation. 24 These patients underwent surgery in the 48 of 93 hospitals described earlier. In all cases, the entire primary tumor was removed with negative histologic margins of resection (R0). The surgical procedures included D1 resection for 4 patients, D2 for 77, and D3 for 121 in terms of the level of lymph node dissection. 26 The regional lymph nodes of colon cancer were anatomically classified to three groups on the basis of the distance from the primary tumor: N1, indicating paracolic lymph nodes; and N2 and N3 lymph nodes, which are respectively distributed along and at the root of the main artery supplying the primary tumor. 26 The surgical procedures of D1, D2, and D3 correspond to colon resection with dissection of N1, N2, and N3 lymph nodes, respectively. 26 All patients agreed to be registered in the CIP study and enrolled in the 28 Postoperative survival rates were compared by the Kaplan-Meier method. There were no differences between the original cohort of patients in the CIP study and the present cohort in terms of the clinical and histopathologic characteristics of the tumor, the proportion of patients administered PSK, or the five-year survival rate (Supplementary Table 1 ).
Thus, there was no statistical bias in the selection of patients from the original cohort for this study. To determine the factors permitting prediction of patients who benefit from the different forms of adjuvant anticancer treatments, clinical and histopathologic parameters/variables and patterns of "-catenin activation in the tumors were analyzed in relation to the survival rates of patients receiving PSK + 5-FU and those receiving 5-FU alone. We also examined the relationship between the presence of the active form of NF-kB (p65 subunit) 29 and "-catenin activation in the tumors to investigate whether immunotherapeutic effect of PSK can be attributed to inhibition of NFkB activity. 
Expression of "-Catenin and the Active Form (p65 Subunit) of NF-kB
It is well documented that "-catenin is stabilized and translocated to the nucleus in a transcriptionally active form, 17, 18 and that the nuclear localization of the p65 subunit of NF-kB represents its active form. 29 To identify the state of activation of "-catenin and NF-kB in the tumors, on the basis of the known correlation between their activities and subcellular localizations, 17, 18, 29 the sections representative of the features of the colon tumors (histologic type and depth of invasion) were selected for immunohistochemical examination of the presence and localization of the two molecules, using the monoclonal antibodies to "-catenin (diluted 1:100; Transduction, Lexington, KY) and the p65 subunit of NF-kB (diluted 1:100; Chemicon, Temecula, CA).
21,24
"-catenin expression was classified into three patterns 21, 22 : membranous expression, similar to that in normal colonic mucosa; NAd, defined as "-catenin-positive nuclei in cells throughout the tumor; and NAinv, which refers to "-catenin-positive nuclei in cancer cells in the deepest part of the tumor, with cells in other parts of the tumor showing membranous expression (Figs. 1 A-C). NF-kB activation was defined by nuclear localization of the p65 subunit in tumor cells (Fig. 1D ). Using these definitions, two well-trained investigators (AO, MM), who were blind to the clinical parameters and outcomes of the patients and the histopathologic characteristics of the tumors, independently reviewed specimens and reached agreement on the expression patterns of "-catenin and the p65 subunit of NF-kB in all tumor samples.
Statistical Analysis of the Data and Survival Rates
The clinical and histopathologic parameters and patterns of "-catenin expression in the tumors were compared by the chi-squared test. A significant difference was verified by the adjusted log-rank test. RFS was calculated by counting the number of patients who had recurrence; CDS included only patients who died of cancer. In analysis of RFS and CDS, patients who died of a disease other than recurrence were censored at the date of death. Survival curves were generated by the Kaplan-Meier method. Statistical differences in survival rates were determined by the log-rank test, and the factors influencing survival rates were evaluated by multivariate analysis using the Cox proportional hazards model. 30 All analyses were performed by using Statistical Analysis System software (SAS \ version 8.2; SAS Institute Inc., Cary, NC). Two-tailed P values <0.05 were considered significant.
RESULTS

Characteristics of Patients
The patients in this study included 110 males and 92 females (age range, 24-75 years). Of these patients, 99 underwent adjuvant treatment with PSK and 5-FU (PSK group), and 103 were treated with 5-FU alone (5-FU group). The two groups of patients had similar clinical and histopathologic characteristics and tumor stages with no statistical difference Figure 2 . Comparison of recurrence-free survival (RFS), cancer death survival (CDS), and overall survival (OS) rates of patients with colon cancer with diffuse nuclear accumulation-type "-catenin activation, according to the forms of adjuvant therapy. Survival rates were calculated by the Kaplan-Meier method. A. All cases. B. Cases with tumor in Stage 3; solid line, polysaccharide K group; dotted line, 5-fluorouracil group. P values were calculated by the log-rank test (p1) and the age-adjusted log-rank test (p2). Cox regression model was used to calculate the hazard ratio.
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We divided the patients into three groups according to the patterns of expression and subcellular localization of "-catenin in the tumor. Two distinct patterns of "-catenin activation were found: NAd in 89 cases, and NAinv in 18 cases. The remaining 95 cases showed no "-catenin activation (NA (-): only membranous expression). As previously reported, 21 the tumor stages of the patients with the NAinv-type "-catenin activation were more advanced (P = 0.019), and there was a higher incidence of tumor recurrence (P = 0.003), resulting in poorer clinical outcomes (RFS, 50 percent; CDS and OS, 55.6 percent) than in patients with NAd-type activation (RFS, 75.3 percent; CDS, 84.1 percent; OS, 82 percent) and in those without activation (RFS, 81.1 percent; CDS, 89.3 percent; OS, 86.3 percent). There was no difference in survival rates between the last two groups of patients. 21 In each of these groups, the patients in the PSK group and those in the 5-FU group showed similar variables listed in Table 1 , with the exceptions of age and survival rates in the patients with NAd-type "-catenin activation (detailed later). Nuclear localization of the NF-kB p65 subunit in the tumor cells was detected in 64 patients (32 percent) . No significant association was found between subcellular localization of NF-kB and clinical and histopathologic characteristics, "-catenin expression pattern (Supplementary Table 2 ), or patient survival rates (data not shown).
COMPARISON OF PATIENT SURVIVAL RATES
We compared the survival rates of patients treated with and without PSK in each of the three groups of patients with respect to "-catenin status (Table 1) . Treatment with PSK was not associated with improved survival in the patients without "-catenin activation or in those with NAinv-type activation. However, in PSK = polysaccharide K; 5-FU = 5-fluorouracil; RFS = recurrence-free survival; CDS = cancer death survival; OS = overall survival; NS = not significant; NA = nuclear accumulation; NA (j) = no "-catenin activation; NAd = diffuse nuclear accumulation-type "-catenin activation; NAinv = "-catenin activation in the tumor invasion front.
Data are percentages unless otherwise indicated. Figure 2B . Statistical difference was determined by an age-adjusted log-rank test.
patients with NAd-type activation, CDS and OS of the PSK group were significantly higher than those of the 5-FU group according to the log-rank test ( Fig. 2A) . In contrast to the other two groups, in this case the patients_ ages in the PSK group were higher than those in the 5-FU group. Comparison of survival rates by an age-adjusted log-rank test showed a significantly higher RFS in the patients of the PSK group. These results indicate an association between treatment with PSK and improved prognosis in patients with NAd-type "-catenin activation. We considered tumor stage in relation to survival rates in patients with NAd-type "-catenin activation (Table 2 ). For tumors of TNM Stages 1 and 2, there was no difference in survival rates between the 5-FU and PSK groups. However, for tumors of the Stage 3, patients in the PSK group had significantly higher CDS and OS than those in the 5-FU group, according to an age-adjusted log-rank test (Fig. 2B) .
We compared the survival rates of patients in relation to the status of "-catenin activation in the PSK and 5-FU groups (Table 3 ). In the 5-FU group, survival rates increased in the following order: patients without "-catenin activation, patients with NAd-type activation, and patients with NAinv-type activation. A significant difference in survival rates was found between the absence and presence of "-catenin activation but not between the two types of its activation. By contrast, in the PSK group, the survival rates of the patients with no "-catenin activation and NAd-type activation were similar and better than those in the patients with NAinv-type activation. This indicates that treatment with PSK is associated with longer survival of patients with NAdtype "-catenin activation.
To investigate the gain-of-survival effect of PSK in the patients with NF-kB activation, we compared the survival rates of the patients with respect to NF-kB status and type of adjuvant therapy. In the cases without NF-kB activation, there was no difference in survival rates between the PSK and 5-FU groups (Fig. 3A) . Among the cases with NF-kB activation, survival rates were higher in the patients treated with PSK than in those treated with 5-FU (Fig. 3B) , Table 4 . although the statistical significance was marginal. In view of the reported association between "-catenin and NF-kB activation in colorectal cancer, 23, 24 we investigated the influence of NF-kB activation and type of adjuvant therapy on the survival of patients with NAd-type "-catenin activation. A statistical analysis using the Cox proportional hazards model showed no significant gain-of-survival effect of the immunochemotherapy (Table 4) . To explore the factors affecting the survival of patients with NAd-type "-catenin activation, the influence of the clinical and histopathologic characteristics and adjuvant treatment with PSK was analyzed by using the Cox proportional hazards model (Table 5) . A multivariate analysis indicated that advanced tumor stage (TNM Stage 3) and type of adjuvant therapy independently affected the fiveyear survival rates of these patients.
DISCUSSION
In this study, we found a survival advantage of adjuvant treatment with PSK in patients with colon cancer with NAd-type "-catenin activation in the primary tumor but not in patients with NAinv-type activation or those without activation. When survival rates in relation to the status of "-catenin activation were compared in the 5-FU group, patients without "-catenin activation had higher survival rates than those with either type of activation. By contrast, the same comparison in the PSK group showed that patients with NAinv-type activation had lower survival rates than those in the other two groups. These results indicate that immunochemotherapy with PSK would have improved the postoperative survival for patients with NAd-type "-catenin activation. This is supported by a multivariate analysis demonstrating that the protocol of adjuvant treatment (i.e., PSK + 5-FU vs. 5-FU) was an independent survival factor for patients with NAd-type "-catenin activation. Consequently, the presence of NAd-type "-catenin activation is a factor that identifies patients who would receive a survival benefit from immunochemotherapy with PSK.
In contrast to the cases with NAd-type "-catenin activation, no survival advantage of PSK treatment was found in the two other groups of patients. The patients without "-catenin activation had a favorable prognosis irrespective of the type of adjuvant treatment, whereas the NAinv group faced an unfavorable outcome regardless of the type of adjuvant therapy, indicating that malignancy of these patients_ tumors was so high that they were refractory to surgical or chemotherapeutic intervention. These results are consistent with the findings that we reported previously concerning the two cohorts of patients with colon cancer. 21, 22 A number of substances and factors have been analyzed for association with the prognosis of patients with stomach cancer undergoing immunochemotherapy with PSK. They included degree of dendritic cell infiltration into the tumor, immunosuppressive acidic protein level, glycosidically bound sialic-acid level, and granulocytes/lymphocytes ratio in peripheral blood sampled before surgery. [11] [12] [13] [14] These parameters were shown to be correlated with prognosis in the patients treated with PSK; however, none of them were associated with a beneficial effect of PSK on survival. In the tumor of patients with colon cancer, the level of expression of thymidylate synthase, which is an initial target of fluoropyrimidine-based chemotherapy, was reported to be a prognostic factor and to affect the outcome of adjuvant chemotherapy. [31] [32] [33] In our recent study, however, we found no association between the expression level of this enzyme and the survival advantage of treatment with PSK. 34 It is important to understand the mechanisms underlying the effect of PSK on tumors with "-catenin activation. As an immunopotentiating biologic response modifier, PSK has been shown to shield the host immune system from damage by chemotherapeutic agents, thus allowing more efficient treatments. 10 The possible ways in which PSK reinforces host immune responses include: induction of cytokines, such as interleukin-1 (IL-1), IL-6, IL-8, tumor necrosis factor-a, or monocyte chemotactic and activating factor; activation of immunologic effector cells, including cytotoxic T lymphocytes, natural killer cells, and dendritic cells; inhibition and direct neutralization of immunosuppressive substances overproduced in response to the cancer; and augmentation of human leukocyte antigen class I expression. [35] [36] [37] [38] [39] [40] [41] Another important anti-cancer function of PSK is its effect on apoptosis of cancer cells. 42 As for its potential chemotherapeutic effect, in pancreatic cancer cells, PSK inhibited NF-kB activation, which resulted in inactivation of cellular inhibitor of apoptosis protein and increased caspase-3 activity, and rendered the cancer cells susceptible to apoptosis in response to a low-dose of docetaxel.
We have demonstrated that, in colon cancer, activated "-catenin up-regulates "-TrCP, which targets IkB for degradation, 23 thereby leading to NF-kB activation and inhibition of apoptosis. 24 In the present study, we demonstrated a positive effect of PSK on the survival of patients with "-catenin or NF-kB activation. The interaction between "-catenin and NF-kB pathways suggests that PSK might more effectively target tumor cells with "-catenin activation than those without activation. This is probably one reason for the survival advantage of immunochemotherapy with PSK in patients with colon cancer with "-catenin activation.
In this study, we investigated "-catenin activation in colon cancers by an immunohistochemical method. It was recently reported that levels of "-catenin mRNA are increased in the plasma of patients with colorectal cancer and that the level is correlated with tumor stage. 43 In preliminary, we have found higher "-catenin protein levels in the plasma of patients with colorectal cancer with "-catenin activation than in those without activation or in healthy subjects. Therefore, a blood test that measures "-catenin mRNA and/or protein levels might be useful for identifying patients with colon cancer who could benefit from immunochemotherapy with PSK. W/D = well-differentiated adenocarcinoma; M/D = moderately differentiated adenocarcinoma; P/D = poorly differentiated adenocarcinoma; RFS = recurrence-free survival; CDS = cancer death survival; OS = overall survival; NA (j), no "-catenin activation; NAd = diffuse-type "-catenin activation; NAinv = "-catenin activation in the tumor invasion front; 5-FU = 5-fluorouracil; PSK = protein-bound polysaccharide K; NF-kB = nuclear factor-kB; (j) = no activation or absence of nuclear accumulation; (+) = activated or presence of nuclear accumulation. a,b Statistical difference determined by chi-squared test: a P = 0.034; b P < 0.001.
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